More to the RAS Story: KRAS G12C Inhibition, Resistance Mechanisms, and Moving Beyond KRAS G12C
The DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.
Abstract
Despite the discovery of RAS oncogenes in human tumor DNA 40 years ago, the development of effective targeted therapies directed against RAS has lagged behind those more successful advancements in the field of therapeutic tyrosine kinase inhibitors targeting other oncogenes such as EGFR, ALK, and ROS1. The discoveries that (1) malignant RAS oncogenes differ from their wild-type counterparts by only a single amino acid change and (2) covalent inhibition of the cysteine residue at codon 12 of KRAS G12C in its inactive GDP-bound state resulted in effective inhibition of oncogenic RAS signaling and have catalyzed a dramatic shift in mindset toward KRAS-driven cancers. Although the development of allele-selective KRAS G12C inhibitors has changed a treatment paradigm, the clinical activity of these agents is more modest than tyrosine kinase inhibitors targeting other oncogene-driven cancers. Heterogeneous resistance mechanisms generally result in the restoration of RAS/mitogen-activated protein kinase pathway signaling. Many approaches are being evaluated to overcome this resistance, with many combinatorial clinical trials ongoing. Furthermore, because KRAS G12D and KRAS G12V are more prevalent than KRAS G12C , there remains an unmet need for additional therapeutic strategies for these patients. Thus, our current translational standing could be described as “the end of the beginning,” with additional discovery and research innovation needed to address the enormous disease burden imposed by RAS-mutant cancers. Here, we describe the development of KRAS G12C inhibitors, the challenges of resistance to these inhibitors, strategies to mitigate that resistance, and new approaches being taken to address other RAS-mutant cancers.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Expression of the identified KRAS mutants was sufficient to confer resistance to KRAS G12C inhibitors in KRAS G12C cancer cells [49, 51, 60].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [60]
In the citing paper
“The genetic alterations identified in these studies are highly heterogeneous and may mediate therapeutic resistance via diverse mechanisms, such as changing inhibitor binding affinity, reactivating KRAS activity, and bypassing KRAS-mediated signaling [54, 56].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [56]
Citations
Cites
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607
PROTAC targeted protein degraders: the past is prologue
Békés, M., Langley, D. R., & Crews, C. M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00371-6 · Cited by 3,395
A view on drug resistance in cancer
Vasan, N., Baselga, J., & Hyman, D. M. (2019) · Nature · doi:10.1038/s41586-019-1730-1 · Cited by 2,770
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
Zou, W., Wolchok, J. D., & Chen, L. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad7118 · Cited by 2,400
The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277
Drugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997
AACR Project GENIE: Powering Precision Medicine through an International Consortium
The AACR Project GENIE Consortium, The AACR Project GENIE Consortium, André, F., Arnedos, M., Baras, A. S., Baselga, J., Bedard, P. L., Berger, M. F., Bierkens, M., Calvo, F., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0151 · Cited by 1,964
RAS Proteins and Their Regulators in Human Disease
Simanshu, D. K., Nissley, D. V., & McCormick, F. (2017) · Cell · doi:10.1016/j.cell.2017.06.009 · Cited by 1,943
Self-citation
Research works printed but not linked: 12
- Healy FM, Br J Pharmacol.
- Proulx-Rocray F, 2021, J Clin Oncol., 39
- Skoulidis F, 2021, J Clin Oncol., 39
- Brana I, 2021, J Clin Oncol., 39
- Hofmann MH, 2021, Cancer Res., 81
- Gort E, 2020, J Clin Oncol., 38
- Gandara D, 2021, Mol Cancer Ther., 20
- Ramalingam S, 2021, Mol Cancer Ther., 20
- Koltun E, 2021, Cancer Res., 81
- Krebs MG, 2021, Cancer Res., 81
- Ricciuti B, Clin Cancer Res.
- Boumelha J, 2022, Cancer Immunol Res., 10
Cited by
Molecular targeted therapy for anticancer treatment
Min, H.-Y., & Lee, H.-Y. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00864-3 · Cited by 569
Translational and therapeutic evaluation of RAS-GTP inhibition by RMC-6236 in RAS-driven cancers
Jiang, J., Jiang, L., Maldonato, B. J., Wang, Y., Holderfield, M., Aronchik, I., Winters, I. P., Salman, Z., Blaj, C., Menard, M., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0027 · Cited by 343
“We hypothesized that, in contrast to mutant RAS-addicted tumor cells, normal cells have reduced levels and/or dependence on RAS-GTP and use homeostatic mechanisms to restore equilibrium following perturbation of RAS signaling (43, 44).”
KRAS inhibitors: resistance drivers and combinatorial strategies
Isermann, T., Sers, C., Der, C. J., & Papke, B. (2025) · Trends in Cancer · doi:10.1016/j.trecan.2024.11.009 · Cited by 196
“Loss of MET function through siRNA depletion of MET or by treatment with the MET inhibitor crizotinib restored sensitivity to sotorasib treatment both in vitro and in vivo [75].”
InfluentialTumour-selective activity of RAS-GTP inhibition in pancreatic cancer
Wasko, U. N., Jiang, J., Dalton, T. C., Curiel-Garcia, A., Edwards, A. C., Wang, Y., Lee, B., Orlen, M., Tian, S., Stalnecker, C. A., et al. (2024) · Nature · doi:10.1038/s41586-024-07379-z · Cited by 209
Chapeau, E. A., Sansregret, L., Galli, G. G., Chène, P., Wartmann, M., Mourikis, T. P., Jaaks, P., Baltschukat, S., Barbosa, I. A. M., Bauer, D., et al. (2024) · Nature Cancer · doi:10.1038/s43018-024-00754-9 · Cited by 159
“Overcoming resistance to KRAS G12C inhibitors remains a challenge, prompting ongoing clinical trials that investigate combination therapies 12 .”
A neomorphic protein interface catalyzes covalent inhibition of RAS G12D aspartic acid in tumors
Weller, C. E., Burnett, G. L., Jiang, L., Chakraborty, S., Zhang, D., Vita, N. A., Dilly, J., Kim, E., Maldonato, B. J., Seamon, K. J., et al. (2025) · Science · doi:10.1126/science.ads0239 · Cited by 78
Maciag, A. E., Stice, J. P., Wang, B., Sharma, A. K., Chan, A. H., Lin, K., Singh, D., Dyba, M. D., Yang, Y., Setoodeh, S., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0840 · Cited by 74
“9–11 ).”
Self-citationSingh, S. P., Bhaskar, R., Ghosh, S., Yarlagadda, B., Singh, K. K., Verma, P., Sengupta, S., Mladenov, M. I., Hadzi‐Petrushev, N., Stojchevski, R., et al. (2025) · Cancers · doi:10.3390/cancers17071082 · Cited by 69
“Since then, many other proto-OGs have been identified, including KRAS (Kirsten rat sarcoma viral oncogene homolog) [10,11], BRAF (B-raf proto-OG, serine/threonine kinase) [11,12], and EGFR (epidermal growth factor receptor) [13].”
The current landscape of using direct inhibitors to target KRASG12C-mutated NSCLC
Batrash, F., Kutmah, M., & Zhang, J. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00453-8 · Cited by 43
“The first of these mechanisms includes mutations of WT RAS homologs (HRAS, NRAS, and MRAS) that can signal for downstream activation and proliferation of the RAF/MAPK pathway [89, 90].”
BackgroundMethodInfluentialZhang, J., Lim, S. M., Yu, M. R., Chen, C., Wang, J., Wang, W., Rui, H., Lu, J., Lü, S., Mok, T. S. K., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0006 · Cited by 42
Mizrahi, D., Lai, J. K. L., Wareing, H., Ren, Y. P., Li, T., Swain, C. T. V., Smith, D. P., Adams, D. H., Martiniuk, A. L. C., & David, M. (2023) · British Journal of Sports Medicine · doi:10.1136/bjsports-2023-107372 · Cited by 35
Hu, Z., & Martí, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213865 · Cited by 25
Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments
Torres-Jiménez, J., Espinar, J. B., Bote, H., Berjaga, M. Z., Esteban-Villarrubia, J., Fraile, J. Z., & Paz-Ares, L. G. (2024) · Drugs · doi:10.1007/s40265-024-02030-7 · Cited by 28
“Discovery of the cysteine 12 residue of mutant KRAS G12C adjacent to a small pocket (P2, switch II region) that was only available in the inactive KRAS-GDP state revolutionized the field of targeted KRAS therapy [84].”
Contreras, C. T., Falke, J. D., Seifert, D., Schneider, C., Krauß, L., Fang, X., Müller, D., Demirdizen, E., Spitzner, M., Oliveira, T. D., et al. (2024) · Molecular Oncology · doi:10.1002/1878-0261.13725 · Cited by 22
The role of molecular testing in pancreatic cancer
Zhen, D. B., Safyan, R. A., Konick, E. Q., Nguyen, R., Pritchard, C. C., & Chiorean, E. G. (2023) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848231171456 · Cited by 18
Regulatory approval of clinical trials: is it time to reinvent the wheel?
Saleh, M. N., Sharma, K., Shamshudin, A., Obayo, I., Gondi, S., & Karimi, N. (2024) · BMJ Global Health · doi:10.1136/bmjgh-2023-013727 · Cited by 16
KRASG12C mutant lung adenocarcinoma: unique biology, novel therapies and new challenges
Moldvay, J., & Tímár, J. (2024) · Pathology & Oncology Research · doi:10.3389/pore.2023.1611580 · Cited by 19
Artificial intelligence across oncology specialties: current applications and emerging tools
Kang, J., Lafata, K. J., Kim, E., Yao, C. M. K. L., Lin, F. P. Y., Rattay, T., Nori, H., Katsoulakis, E., & Lee, C. I. (2024) · BMJ Oncology · doi:10.1136/bmjonc-2023-000134 · Cited by 17
Molecular Landscape and Therapeutic Strategies against Colorectal Cancer
Patel, A., & Gulhati, P. (2024) · Cancers · doi:10.3390/cancers16081551 · Cited by 14
“Mechanisms of acquired resistance to KRAS G12C inhibitors include MAPK pathway mutations, transformation from adenocarcinoma to squamous histology, alternative KRAS alterations, and a high degree of KRAS G12C amplification [75].”
BackgroundResistance to KRAS inhibition in advanced non-small cell lung cancer
Sreter, K. B., Catarata, M. J., von Laffert, M., & Frille, A. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1357898 · Cited by 12
Gluing GAP to RAS Mutants: A New Approach to an Old Problem in Cancer Drug Development
Ranđelović, I., Nyíri, K., Koppány, G., Baranyi, M., Tóvári, J., Kigyós, A., Tímár, J., Vértessy, B. G., & Grolmusz, V. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052572 · Cited by 10
Morel, M., & Long, W. (2023) · Molecular Oncology · doi:10.1002/1878-0261.13554 · Cited by 11
“Unfortunately, patients either have intrinsic resistance to these drugs or inevitably develop resistance upon drug treatment [4,27,29 – 32].”
BackgroundDual inhibition of HERs and PD-1 counteract resistance in KRASG12C-mutant head and neck cancer
Novoplansky, O., Jagadeeshan, S., Prasad, M., Yegodayev, K. M., Marripati, D., Shareb, R. A., Greenshpan, Y., Mathukkada, S., Lulu, T. B., Bhattacharya, B., et al. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03227-0 · Cited by 8
“…RAS signaling results in the loss of feedback and an increase in upstream signaling pathways through the activation of growth factor receptors [26, 75] Activation of RAS pathway can trigger signaling through wild-type HRAS or NRAS proteins expressed in all cancer cells with mutant KRAS or…”
With a little help from my T friends: T cells increase efficacy of KRAS (G12D) inhibitors
Mainardi, S. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.100950 · Cited by 8
“The most clinically advanced of those drugs, targeting specifically the G12C mutant, quickly made it through clinical trials, and thanks to their favorable toxicity profile and promising anti-tumor efficacy, two of them have been approved for the treatment of KRAS-G12C-mutant lung cancer.(2) Unfortunately, KRAS-G12C m…”
BackgroundDifferential Response and Resistance to KRAS-Targeted Therapy
Liu, Z., Lenz, H., Yu, J., & Zhang, L. (2025) · Molecular Carcinogenesis · doi:10.1002/mc.23908 · Cited by 7
“Expression of the identified KRAS mutants was sufficient to confer resistance to KRAS G12C inhibitors in KRAS G12C cancer cells [51, 53, 62].”
How KRAS Mutations Impair Intrinsic GTP Hydrolysis: Experimental and Computational Investigations
Song, L. F., Rabara, D., Bali, S. K., Pei, J., Lau, E. Y., Kirshner, D. A., Lightstone, F. C., McCormick, F. P., Stephen, A. G., & Yang, Y. (2025) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5c02061 · Cited by 7
Self-citationClinical Progress of KRAS-targeted Therapies: What next?
Nagasaka, M., & Azmi, A. S. (2022) · Future Medicinal Chemistry · doi:10.4155/fmc-2022-0128 · Cited by 7
Zhou, C., Liu, Y., Liu, H., Lü, J., Zhang, B., Zhu, L., Wang, S., Lei, H.-M., & Han, B. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07992-4 · Cited by 6
Hindul, N. L., Abbott, L. R., Adan, S. M. D., Straatman, K. R., Fry, A. M., Hirota, K., & Tanaka, K. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107409 · Cited by 6
“It also redefines the current and future challenges, including improving inhibitor efficacies, mitigating acquired resistance, and developing new inhibitors that cover all oncogenic RAS isoforms (11,31,32).”
BackgroundLee, A. T., & Nagasaka, M. (2024) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s492126 · Cited by 7
Mateo-Victoriano, B., Samaranayake, G. J., Pokharel, S. P., Sahayanathan, G. J., Jayaraj, C. J., Troccoli, C. I., Watson, D. C., Mohsen, M. G., Guo, Y., Kool, E. T., et al. (2025) · Redox Biology · doi:10.1016/j.redox.2025.103610 · Cited by 4
Wallen, Z. D., Nesline, M., Tierno, M. B., Roos, A., Schnettler, E. K., Husain, H., Sathyan, P., Caveney, B. J., Eisenberg, M. T., Severson, E. A., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1473327 · Cited by 5
Ghosh, S., Fan, F., Powell, R. T., Park, Y. S., STEPHAN, C. C., Kopetz, S., Ellis, L. M., & Bhattacharya, R. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241303302 · Cited by 4
“41,42 Novel agents targeting other KRAS and pan-KRAS mutations have also been developed and are now in various stages of preclinical or clinical assessment for efficacy in various cancers, including CRC. 7–10 While KRAS G12C inhibitors have demonstrated efficacy in non-small-cell lung cancer, they…”
Detection of aberrant locomotor activity in a mouse model of lung cancer via home cage monitoring
Tomanelli, M., Guffanti, F., Vargiu, G., Micotti, E., Rigamonti, M., Tumiatti, F., Caiola, E., Marabese, M., & Broggini, M. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1504938 · Cited by 4
Updates on molecular targets and clinical trials with targeted therapies for pancreatic cancer
Safyan, R. A., & Chiorean, E. G. (2025) · Surgical Oncology · doi:10.1016/j.suronc.2025.102268 · Cited by 4
Patel, H. V., Smith, A. E., Chan, S., Gasendo, J. G., Jombik, A., Greer, J. E., Samantaray, T., Kessler, L. V., Mitra, A., Zhu, X., et al. (2026) · Cancer Research · doi:10.1158/0008-5472.can-25-2764 · Cited by 6
“Mechanisms underlying clinical resistance are heterogeneous but ultimately converge on reactivating the MAPK pathway or compensatory PI3K–AKT–mTOR signaling (6, 7).”
KRAS combination strategies: How well aligned is clinical and preclinical research?
Nadal, E., Ambrogio, C., Santamaría, D., & Lindsay, C. R. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-21861-3.00018-8 · Cited by 2
Self-citationMelosky, B. L., Juergens, R. A., Banerji, S. O., Sacher, A. G., Wheatley‐Price, P., Snow, S. L., Tsao, M., Leighl, N. B., Martins, I., Cheema, P. K., et al. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241308784 · Cited by 4
Cancer Disease-Oriented-Drug Development Examples
Gandía, D., & Cecilia, S. (2022) · Cancer Studies and Molecular Medicine - Open Journal · doi:10.17140/csmmoj-7-132
Making incurable pancreatic cancer curable
An, J., Xie, D., & Xie, K. (2023) · Malignancy Spectrum · doi:10.1002/msp2.19
KRAS in Stage IV Non-Small Cell Lung Cancer
(2025) · Frontiers research topics · doi:10.3389/978-2-8325-6151-5 · Cited by 1
New Diagnostic and Therapeutic Possibilities in Lung Cancer
(2025) · Frontiers Media SA eBooks · doi:10.3389/978-2-8325-6297-0
A Versatile Single-Cell Analysis Pipeline for High-Content Screening by Live-Cell Imaging
Zyss, D. (2024) · theses.fr (ABES) · doi:10.70675/2b6332a0zeb61z41a6z9e7az03aa623af8b9
Drug repurposing in KRAS G12C-mutant NSCLC: a focus on resistance mechanisms and clinical strategies
Jain, A., Rosell, R., Dharmashekara, C., Shreevatsa, B., González-Cao, M., Shivakumar, A., Kollur, S. P., Prasad, A., Shivamallu, C., & Prasad, M. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05533-0
“Histological transformation from adenocarcinoma to squamous cell (Lietman et al. 2022).”
Jeon, E., Song, J., & Sim, T. (2026) · Future Medicinal Chemistry · doi:10.1080/17568919.2026.2719780
Adhao, V., & Patil, S. N. (2026) · INNOSC Theranostics and Pharmacological Sciences · doi:10.36922/itps026270024
Emerging Strategies for KRAS Inhibition in Cancer: From G12C to Pan-RAS and Beyond
Flynn, C. R., Matallanas, D., Kölch, W., Cowzer, D., & Duffy, A. G. (2026) · Journal of Molecular and Clinical Medicine · doi:10.31083/jmcm51252
Metadata
- Authors
- Lietman, C. D., Johnson, M. L., McCormick, F., & Lindsay, C. R.
- Affiliations
- Sarah Cannon (US)
- UCSF Helen Diller Family Comprehensive Cancer Center (US)
- University of Manchester (GB)
- Venue
- American Society of Clinical Oncology Educational Book
- Published
- 2022-07
- Volume
- 42
- Issue
- 42
- Pages
- 205-217
- ISSN
- 1548-8748 (ISSN-L)
- 1548-8756
- OpenAlex
- W4280497507
- Cited by
- 44
- References
- 90
- Citations by year
- 2026: 2 · 2025: 8 · 2024: 23 · 2023: 7 · 2022: 4
- FWCI
- 3.43
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Society of Clinical Oncology Educational Book (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- KRAS G12C inhibitors, KRAS mutation, oncogenic Ras, drug resistance mechanisms, KRAS G12D, KRAS G12V, targeted cancer therapy, combination therapy
- MeSH terms
- Humans, Mutation, Neoplasms, Protein-Tyrosine Kinases, Proto-Oncogene Proteins, Genes, ras, Proto-Oncogene Proteins p21(ras), Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.